The US health industry is in the midst of a transformation to a value-outcome system, which is good for a learning health system, explained Lewis G. Sandy, MD, FACP, senior vice president of clinical advancement at UnitedHealth Group.
Most of the research in cancer economics has been on total cost and cost effectiveness, which is why Veena Shankaran MD, MS, assistant professor in the division of medical oncology at the University of Washington, wanted to have a panel discussion on financial toxicity at the ISPOR 20th Annual Meeting.
Despite fast adoption of electronic health records (EHRs) over the past 5 years, many clinicians have voiced concerns about the unintended clinical consequences of EHR use, such as reduced time for patient-clinician interactions, burdensome data entry tasks for front-line clinicians, and interoperability troubles.
While the concept of informed consent it a good one, there is a fundamental problem with the informed consent and how it is practiced today, writes Harlan Krumholz, MD, SM, professor of cardiology, epidemiology, and public health.


Medical monitoring and counseling can help us track and contain many harmful effects of cancer drug-induced cardiotoxicity. Patient engagement from the very beginning, along with medically advanced testing methods, can help us surmount cardiotoxicity and better ensure that patients receive only the benefits of essential cancer treatment.
Improved survivorship rates among cancer patients has brought a growing awareness of a serious latent impact of chemotherapy and radiation: cardiotoxicity. Despite extensive research on the subject, our understanding of the tools for identifying and preventing these complications is limited.
To promote collaboration and efficiency, the MD Anderson Cancer Center developed an interdisciplinary team–based Heart Success Program to coordinate the management of concurrent cardiomyopathy and HF while the patient is receiving cancer treatment.
With the explosion of new therapies in cancer care, the risk of each new therapy must be clearly understood prior to making treatment decisions with patients. Data from clinical trials alone are insufficient to educate these treatment choices, and real-world evidence from higher-risk populations should be generated to inform these treatment decisions.


Most Popular

AJMC Strategic Alliance